Angkawinitwong Ukrit, Sharma Garima, Khaw Peng T, Brocchini Steve, Williams Gareth R
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
Ther Deliv. 2015 Jan;6(1):59-82. doi: 10.4155/tde.14.98.
When formulated as liquid dosage forms, therapeutic proteins and peptides often show instability during handling as a result of chemical degradation. Solid formulations are frequently required to maintain protein stability during storage, transport and upon administration. Herein we highlight current strategies used to formulate pharmaceutical proteins in the solid form. An overview of the physical instabilities which can arise with proteins is first described. The key solidification techniques of crystallization, freeze-drying and particle forming technologies are then discussed. Examples of current commercial products that are formulated in the solid state are provided and include neutral protamine Hagedorn - insulin crystal suspensions, freeze-dried monoclonal antibodies and leuproride polylactide-co-glycolide microparticles. Finally, future perspectives in solid-state protein formulation are described.
当制成液体制剂时,治疗性蛋白质和肽由于化学降解在处理过程中常常表现出不稳定性。在储存、运输和给药过程中,通常需要固体剂型来维持蛋白质的稳定性。在此,我们重点介绍目前用于将药物蛋白质制成固体形式的策略。首先描述了蛋白质可能出现的物理不稳定性。然后讨论了结晶、冷冻干燥和颗粒形成技术等关键固化技术。提供了当前以固体状态配制的商业产品实例,包括中性鱼精蛋白锌胰岛素晶体悬液、冻干单克隆抗体和亮丙瑞林聚丙交酯-乙交酯微粒。最后,描述了固态蛋白质制剂的未来前景。